E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis

Cell Death and Disease

Volumn 4, Issue 1, 2013, Pages

  Severe N ^a,b   Dieudonne F X ^a,b   Marie, P J ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

bone tumors; Cbl proteins; proteasome; receptor tyrosine kinases; ubiquitin ligases; ubiquitination

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; BETA CATENIN; BONE MORPHOGENETIC PROTEIN 2; BORTEZOMIB; CBL PROTEIN; COLONY STIMULATING FACTOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN RECEPTOR SUBSTRATE 1; PENTAPEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEASOME INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SOMATOMEDIN RECEPTOR; STAT5 PROTEIN; TRANSCRIPTION FACTOR GLI2; TRANSCRIPTION FACTOR RUNX2; TUMOR NECROSIS FACTOR ALPHA; UBIQUITIN PROTEIN LIGASE E3; UBIQUITIN PROTEIN LIGASE;

ACROCEPHALOSYNDACTYLY; BONE DEVELOPMENT; BONE MATRIX; BONE METASTASIS; BONE TUMOR; BONE TURNOVER; CARCINOGENESIS; CELL PROLIFERATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MESENCHYMAL STROMA CELL; OSSIFICATION; OSTEOBLAST; OSTEOCLAST ACTIVITY; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RING FINGER MOTIF; SIGNAL TRANSDUCTION; UBIQUITINATION; ANIMAL; CELL TRANSFORMATION; GENETICS; METABOLISM; NEOPLASM; PATHOLOGY;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; NEOPLASMS; OSTEOGENESIS; PROTO-ONCOGENE PROTEINS C-CBL; RECEPTOR PROTEIN-TYROSINE KINASES; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

MLCS; MLOWN;

EID: 84872202144     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.217     Document Type: Review

References (139)

1. Ciechanover A. Intracellular protein degradation: from a vague idea, through the lysosome and the ubiquitin-proteasome system, and onto human diseases and drug targeting. Cell Death Differ 2005; 12: 1178-1190.
2. Komander D. The emerging complexity of protein ubiquitination. Biochem Soc Trans 2009; 37(Pt 5): 937-953.
3. Dikic I, Wakatsuki S, Walters KJ. Ubiquitin-binding domains - from structures to functions. Nat Rev Mol Cell Biol 2009; 10: 659-671.
4. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550-563.
5. Ciechanover A. The ubiquitin proteolytic system: from an idea to the patient bed. Proc Am Thorac Soc 2006; 3: 21-31.
6. Dikic I, Robertson M. Ubiquitin ligases and beyond. BMC Biol 2012; 10: 22.
7. Husnjak K, Dikic I. Ubiquitin-binding proteins: decoders of ubiquitin-mediated cellular functions. Annu Rev Biochem 2012; 81: 291-322.
8. de Bie P, Ciechanover A. Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms. Cell Death Differ 2011; 18: 1393-1402.
9. Edwards JR, Mundy GR. Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol 2011; 7: 235-243.
10. Harada S, Rodan GA. Control of osteoblast function and regulation of bone mass. Nature 2003; 423: 349-355. (Pubitemid 40852710)
11. Lian JB, Stein GS, Stein JL, van Wijnen AJ. Transcriptional control of osteoblast differentiation. Biochem Soc Trans 1998; 26: 14-21. (Pubitemid 28064293)
12. Marie PJ. Transcription factors controlling osteoblastogenesis. Arch Biochem Biophys 2008; 473: 98-105.
13. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000; 21: 115-137. (Pubitemid 32275592)
14. Lian JB, Stein GS. Runx2/Cbfa1: a multifunctional regulator of bone formation. Curr Pharm Des 2003; 9: 2677-2685. (Pubitemid 37456017)
15. Teti A. Bone development: overview of bone cells and signaling. Curr Osteoporos Rep 2011; 9: 264-273.
16. Wu S, De Luca F. Inhibition of the proteasomal function in chondrocytes down-regulates growth plate chondrogenesis and longitudinal bone growth. Endocrinology 2006; 147: 3761-3768. (Pubitemid 44079380)
17. Yaccoby S. Osteoblastogenesis and tumor growth in myeloma. Leuk Lymphoma 2010; 51: 213-220.
18. Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN et al. Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice. J Clin Invest 2008; 118: 491-504. (Pubitemid 351206540)
19. Giuliani N, Morandi F, Tagliaferri S, Lazzaretti M, Bonomini S, Crugnola M et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110: 334-338. (Pubitemid 47026851)
20. Oyajobi BO, Garrett IR, Gupta A, Flores A, Esparza J, Munoz S et al. Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease. Br J Haematol 2007; 139: 434-438. (Pubitemid 47512190)
21. Uy GL, Trivedi R, Peles S, Fisher NM, Zhang QJ, Tomasson MH et al. Bortezomib inhibits osteoclast activity in patients with multiple myeloma. Clin Lymphoma Myeloma 2007; 7: 587-589.
22. Terpos E, Sezer O, Croucher P, Dimopoulos MA. Myeloma bone disease and proteasome inhibition therapies. Blood 2007; 110: 1098-1104. (Pubitemid 47281403)
23. Goldring MB, Tsuchimochi K, Ijiri K. The control of chondrogenesis. J Cell Biochem 2006; 97: 33-44. (Pubitemid 43050970)
24. Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116: 1202-1209.
25. Nusse R. Wnt signaling in disease and in development. Cell Res 2005; 15: 28-32. (Pubitemid 41653961)
26. Zaman F, Menendez-Benito V, Eriksson E, Chagin AS, Takigawa M, Fadeel B et al. Proteasome inhibition up-regulates p53 and apoptosis-inducing factor in chondrocytes causing severe growth retardation in mice. Cancer Res 2007; 67: 10078-10086. (Pubitemid 47621259)
27. Qiang YW, Hu B, Chen Y, Zhong Y, Shi B, Barlogie B et al. Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 2009; 113: 4319-4330.
28. Garrett IR, Chen D, Gutierrez G, Zhao M, Escobedo A, Rossini G et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 2003; 111: 1771-1782. (Pubitemid 38057757)
29. Zhao M, Qiao M, Harris SE, Chen D, Oyajobi BO, Mundy GR. The zinc finger transcription factor Gli2 mediates bone morphogenetic protein 2 expression in osteoblasts in response to hedgehog signaling. Mol Cell Biol 2006; 26: 6197-6208. (Pubitemid 44204537)
30. von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025-2034. (Pubitemid 47299978)
31. Ang E, Pavlos NJ, Rea SL, Qi M, Chai T, Walsh JP et al. Proteasome inhibitors impair RANKL-induced NF-kappaB activity in osteoclast-like cells via disruption of p62, TRAF6, CYLD, and IkappaBalpha signaling cascades. J Cell Physiol 2009; 220: 450-459.
32. Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S. The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol 2009; 84: 6-14.
33. Zhao M, Qiao M, Oyajobi BO, Mundy GR, Chen D. E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation. J Biol Chem 2003; 278: 27939-27944. (Pubitemid 36899988)
34. Zhao M, Qiao M, Harris SE, Oyajobi BO, Mundy GR, Chen D. Smurf1 inhibits osteoblast differentiation and bone formation in vitro and in vivo. J Biol Chem 2004; 279: 12854-12859. (Pubitemid 38445859)
35. Zhao L, Huang J, Guo R, Wang Y, Chen D, Xing L. Smurf1 inhibits mesenchymal stem cell proliferation and differentiation into osteoblasts through JunB degradation. J Bone Miner Res 2010; 25: 1246-1256.
36. Kaneki H, Guo R, Chen D, Yao Z, Schwarz EM, Zhang YE et al. Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts. J Biol Chem 2006; 281: 4326-4333. (Pubitemid 43847863)
37. Guo R, Yamashita M, Zhang Q, Zhou Q, Chen D, Reynolds DG et al. Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J Biol Chem 2008; 283: 23084-23092.
38. Glimcher LH, Jones DC, Wein MN. Control of postnatal bone mass by the zinc finger adapter protein Schnurri-3. Ann N Y Acad Sci 2007; 1116: 174-181. (Pubitemid 350274333)
39. Jeon EJ, Lee KY, Choi NS, Lee MH, Kim HN, Jin YH et al. Bone morphogenetic protein-2 stimulates Runx2 acetylation. J Biol Chem 2006; 281: 16502-16511.
40. Zhu H, Kavsak P, Abdollah S, Wrana JL, Thomsen GH. A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. Nature 1999; 400: 687-693.
41. Zhang G, Guo B, Wu H, Tang T, Zhang BT, Zheng L et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat Med 2012; 18: 307-314.
42. Bellido T, Ali AA, Plotkin LI, Fu Q, Gubrij I, Roberson PK et al. Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-Apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem 2003; 278: 50259-50272. (Pubitemid 37548867)
43. Yamashita M, Ying SX, Zhang GM, Li C, Cheng SY, Deng CX et al. Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. Cell 2005; 121: 101-113.
44. Li X, Huang M, Zheng H, Wang Y, Ren F, Shang Y et al. CHIP promotes Runx2 degradation and negatively regulates osteoblast differentiation. J Cell Biol 2008; 181: 959-972. (Pubitemid 351846829)
45. Jones DC, Wein MN, Oukka M, Hofstaetter JG, Glimcher MJ, Glimcher LH. Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3. Science 2006; 312: 1223-1227. (Pubitemid 43801150)
46. Zhao L, Huang J, Zhang H, Wang Y, Matesic LE, Takahata M et al. Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1. Stem Cells 2011; 29: 1601-1610.
47. Yang X, Karsenty G. ATF4, the osteoblast accumulation of which is determined post-translationally, can induce osteoblast-specific gene expression in non-osteoblastic cells. J Biol Chem 2004; 279: 47109-47114. (Pubitemid 39518367)
48. Kim M, Nakamoto T, Nishimori S, Tanaka K, Chiba T. A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation. EMBO Rep 2008; 9: 878-884.
49. Dikic I, Szymkiewicz I, Soubeyran P. Cbl signaling networks in the regulation of cell function. Cell Mol Life Sci 2003; 60: 1805-1827. (Pubitemid 37222580)
50. Swaminathan G, Tsygankov AY. The Cbl family proteins: ring leaders in regulation of cell signaling. J Cell Physiol 2006; 209: 21-43. (Pubitemid 44318665)
51. Mohapatra B, Ahmad G, Nadeau S, Zutshi N, An W, Scheffe S et al. Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases. Biochim Biophys Acta 2013; 1833: 122-139.
52. Thien CB, Langdon WY. Cbl: many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2001; 2: 294-307.
53. Tsygankov AY, Teckchandani AM, Feshchenko EA, Swaminathan G. Beyond the RING: CBL proteins as multivalent adapters. Oncogene 2001; 20: 6382-6402. (Pubitemid 32977846)
54. Schmidt MH, Dikic I. The Cbl interactome and its functions. Nat Rev Mol Cell Biol 2005; 6: 907-919.
55. Haglund K, Schmidt MH, Wong ES, Guy GR, Dikic I. Sprouty2 acts at the Cbl/CIN85 interface to inhibit epidermal growth factor receptor downregulation. EMBO Rep 2005; 6: 635-641. (Pubitemid 41122431)
56. Kassenbrock CK, Anderson SM. Regulation of ubiquitin protein ligase activity in c-Cbl by phosphorylation-induced conformational change and constitutive activation by tyrosine to glutamate point mutations. J Biol Chem 2004; 279: 28017-28027. (Pubitemid 38900072)
57. Dou H, Buetow L, Hock A, Sibbet GJ, Vousden KH, Huang DT. Structural basis for autoinhibition and phosphorylation-dependent activation of c-Cbl. Nat Struct Mol Biol 2012; 19: 184-192.
58. Kales SC, Ryan PE, Lipkowitz S. Cbl exposes its RING finger. Nat Struct Mol Biol 2012; 19: 131-133.
59. Thien CB, Langdon WY. Negative regulation of PTK signalling by Cbl proteins. Growth Factors 2005; 23: 161-167. (Pubitemid 43203064)
60. Hunter S, Burton EA, Wu SC, Anderson SM. Fyn associates with Cbl and phosphorylates tyrosine 731 in Cbl, a binding site for phosphatidylinositol 3-kinase. J Biol Chem 1999; 274: 2097-2106.
61. Davies GC, Ettenberg SA, Coats AO, Mussante M, Ravichandran S, Collins J et al. Cbl-b interacts with ubiquitinated proteins; differential functions of the UBA domains of c-Cbl and Cbl-b. Oncogene 2004; 23: 7104-7115. (Pubitemid 39319172)
62. Sanjay A, Houghton A, Neff L, DiDomenico E, Bardelay C, Antoine E et al. Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility. J Cell Biol 2001; 152: 181-195. (Pubitemid 32102446)
63. Dikic I, Giordano S. Negative receptor signalling. Curr Opin Cell Biol 2003; 15: 128-135. (Pubitemid 36332186)
64. Rubin C, Gur G, Yarden Y. Negative regulation of receptor tyrosine kinases: unexpected links to c-Cbl and receptor ubiquitylation. Cell Res 2005; 15: 66-71. (Pubitemid 41653969)
65. Naramura M, Jang IK, Kole H, Huang F, Haines D, Gu H. c-Cbl and Cbl-b regulate T cell responsiveness by promoting ligand-induced TCR down-modulation. Nat Immunol 2002; 3: 1192-1199. (Pubitemid 35469704)
66. Chiusaroli R, Sanjay A, Henriksen K, Engsig MT, Horne WC, Gu H et al. Deletion of the gene encoding c-Cbl alters the ability of osteoclasts to migrate, delaying resorption and ossification of cartilage during the development of long bones. Dev Biol 2003; 261: 537-547. (Pubitemid 37108791)
67. Bruzzaniti A, Neff L, Sanjay A, Horne WC, De Camilli P, Baron R. Dynamin forms a Src kinase-sensitive complex with Cbl and regulates podosomes and osteoclast activity. Mol Biol Cell 2005; 16: 3301-3313. (Pubitemid 40962599)
68. Meng F, Lowell CA. A beta 1 integrin signaling pathway involving Src-family kinases, Cbl and PI-3 kinase is required for macrophage spreading and migration. EMBO J 1998; 17: 4391-4403. (Pubitemid 28362629)
69. Nakajima A, Sanjay A, Chiusaroli R, Adapala NS, Neff L, Itzsteink C et al. Loss of Cbl-b increases osteoclast bone-resorbing activity and induces osteopenia. J Bone Miner Res 2009; 24: 1162-1172.
70. Horne WC, Sanjay A, Bruzzaniti A, Baron R. The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunol Rev 2005; 208: 106-125. (Pubitemid 41746388)
71. Purev E, Neff L, Horne WC, Baron R. c-Cbl and Cbl-b act redundantly to protect osteoclasts from apoptosis and to displace HDAC6 from beta-tubulin, stabilizing microtubules and podosomes. Mol Biol Cell 2009; 20: 4021-4030.
72. Tanaka S, Amling M, Neff L, Peyman A, Uhlmann E, Levy JB et al. c-Cbl is downstream of c-Src in a signalling pathway necessary for bone resorption. Nature 1996; 383: 528-531. (Pubitemid 26346179)
73. Yokouchi M, Kondo T, Sanjay A, Houghton A, Yoshimura A, Komiya S et al. Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J Biol Chem 2001; 276: 35185-35193.
74. Akiyama T, Bouillet P, Miyazaki T, Kadono Y, Chikuda H, Chung UI et al. Regulation of osteoclast apoptosis by ubiquitylation of proapoptotic BH3-only Bcl-2 family member Bim. EMBO J 2003; 22: 6653-6664. (Pubitemid 38009611)
75. Adapala NS, Barbe MF, Langdon WY, Nakamura MC, Tsygankov AY, Sanjay A. The loss of Cbl-phosphatidylinositol 3-kinase interaction perturbs RANKL-mediated signaling, inhibiting bone resorption and promoting osteoclast survival. J Biol Chem 2010; 285: 36745-36758.
76. Sévére N, Miraoui H, Marie PJ. The Casitas B lineage lymphoma (Cbl) mutant G306E enhances osteogenic differentiation in human mesenchymal stromal cells in part by decreased Cbl-mediated platelet-derived growth factor receptor alpha and fibroblast growth factor receptor 2 ubiquitination. J Biol Chem 2011; 286: 24443-24450.
77. Golden LH, Insogna KL. The expanding role of PI3-kinase in bone. Bone 2004; 34: 3-12. (Pubitemid 38142429)
78. Brennan T, Adapala NS, Barbe MF, Yingling V, Sanjay A. Abrogation of Cbl-PI3K interaction increases bone formation and osteoblast proliferation. Calcif Tissue Int 2011; 89: 396-410.
79. Yousfi M, Lasmoles F, Lomri A, Delannoy P, Marie PJ. Increased bone formation and decreased osteocalcin expression induced by reduced Twist dosage in Saethre-Chotzen syndrome. J Clin Invest 2001; 107: 1153-1161. (Pubitemid 32422912)
80. Guénou H, Kaabeche K, Dufour C, Miraoui H, Marie PJ. Down-regulation of ubiquitin ligase Cbl induced by twist haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/Akt signaling and osteoblast proliferation. Am J Pathol 2006; 169: 1303-1311. (Pubitemid 351194365)
81. Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141: 1117-1134.
82. Joazeiro CA, Wing SS, Huang H, Leverson JD, Hunter T, Liu YC. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science 1999; 286: 309-312. (Pubitemid 29484697)
83. Levkowitz G, Waterman H, Zamir E, Kam Z, Oved S, Langdon WY et al. c-Cbl/Sli-1 regulates endocytic sorting and ubiquitination of the epidermal growth factor receptor. Genes Dev 1998; 12: 3663-3674. (Pubitemid 29019647)
84. Miyake S, Mullane-Robinson KP, Lill NL, Douillard P, Band H. Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain. J Biol Chem 1999; 274: 16619-16628.
85. Yokouchi M, Kondo T, Houghton A, Bartkiewicz M, Horne WC, Zhang H et al. Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J Biol Chem 1999; 274: 31707-31712.
86. Pennock S, Wang Z. A tale of two Cbls: interplay of c-Cbl and Cbl-b in epidermal growth factor receptor downregulation. Mol Cell Biol 2008; 28: 3020-3037. (Pubitemid 351556533)
87. Kawai M, Rosen CJ. The insulin-like growth factor system in bone: basic and clinical implications. Endocrinol Metab Clin North Am 2012; 41: 323-333; vi. 88. Mohan S, Kesavan C. Role of insulin-like growth factor-1 in the regulation of skeletal growth. Curr Osteoporos Rep 2012; 10: 178-186.
88. Marie PJ, Miraoui H, Sévére N. FGF/FGFR signaling in bone formation: progress and perspectives. Growth Factors 2012; 30: 117-123.
89. Du X, Xie Y, Xian CJ, Chen L. Role of FGFs/FGFRs in skeletal development and bone regeneration. J Cell Physiol 2012; 227: 3731-3743.
90. Marie PJ. Fibroblast growth factor signaling controlling bone formation: an update. Gene 2012; 498: 1-4.
91. Kratchmarova I, Blagoev B, Haack-Sorensen M, Kassem M, Mann M. Mechanism of divergent growth factor effects in mesenchymal stem cell differentiation. Science 2005; 308: 1472-1477. (Pubitemid 40791302)
92. Ornitz DM, Marie PJ. FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev 2002; 16: 1446-1465. (Pubitemid 34686327)
93. Lomri A, Lemonnier J, Hott M, de Parseval N, Lajeunie E, Munnich A et al. Increased calvaria cell differentiation and bone matrix formation induced by fibroblast growth factor receptor 2 mutations in Apert syndrome. J Clin Invest 1998; 101: 1310-1317. (Pubitemid 28145247)
94. Lemonnier J, Hay̌ E, Delannoy P, Lomri A, Modrowski D, Caverzasio J et al. Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis. J Bone Miner Res 2001; 16: 832-845. (Pubitemid 32332293)
95. Lomri A, Lemonnier J, Delannoy P, Marie PJ. Increased expression of protein kinase Calpha, interleukin-1alpha, and RhoA guanosine 50-triphosphatase in osteoblasts expressing the Ser252Trp fibroblast growth factor 2 receptor Apert mutation: identification by analysis of complementary DNA microarray. J Bone Miner Res 2001; 16: 705-712. (Pubitemid 32230599)
96. Miraoui H, Oudina K, Petite H, Tanimoto Y, Moriyama K, Marie PJ. Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling. J Biol Chem 2009; 284: 4897-4904.
97. Miraoui H, Ringe J, Haupl T, Marie PJ. Increased EFG- And PDGF{alpha}-receptor signaling by mutant FGF-receptor 2 contributes to osteoblast dysfunction in Apert craniosynostosis. Hum Mol Genet 2010; 19: 1678-1689.
98. Miraoui H, Marie PJ. Fibroblast growth factor receptor signaling crosstalk in skeletogenesis. Sci Signal 2010; 3: re9.
99. Andoniou CE, Lill NL, Thien CB, Lupher ML Jr., Ota S, Bowtell DD et al. The Cbl protooncogene product negatively regulates the Src-family tyrosine kinase Fyn by enhancing its degradation. Mol Cell Biol 2000; 20: 851-867. (Pubitemid 30044222)
100. Kaabeche K, Lemonnier J, Le Mée S, Caverzasio J, Marie PJ. Cbl-mediated degradation of Lyn and Fyn induced by constitutive fibroblast growth factor receptor-2 activation supports osteoblast differentiation. J Biol Chem 2004; 279: 36259-36267. (Pubitemid 39128962)
101. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 1998; 17: 7151-7160. (Pubitemid 29002684)
102. Melino G. Discovery of the ubiquitin proteasome system and its involvement in apoptosis. Cell Death Differ 2005; 12: 1155-1157. (Pubitemid 41195098)
103. Kaabeche K, Guénou H, Bouvard D, Didelot N, Listrat A, Marie PJ. Cbl-mediated ubiquitination of alpha5 integrin subunit mediates fibronectin-dependent osteoblast detachment and apoptosis induced by FGFR2 activation. J Cell Sci 2005; 118(Pt 6): 1223-1232. (Pubitemid 40528692)
104. Niethammer P, Delling M, Sytnyk V, Dityatev A, Fukami K, Schachner M. Cosignaling of NCAM via lipid rafts and the FGF receptor is required for neuritogenesis. J Cell Biol 2002; 157: 521-532. (Pubitemid 34839814)
105. Haglund K, Ivankovic-Dikic I, Shimokawa N, Kruh GD, Dikic I. Recruitment of Pyk2 and Cbl to lipid rafts mediates signals important for actin reorganization in growing neurites. J Cell Sci 2004; 117(Pt 12): 2557-2568. (Pubitemid 38877851)
106. Lemonnier J, Hay̌ E, Delannoy P, Fromigué O, Lomri A, Modrowski D et al. Increased osteoblast apoptosis in apert craniosynostosis: role of protein kinase C and interleukin-1. Am J Pathol 2001; 158: 1833-1842. (Pubitemid 32422948)
107. Dufour C, Guénou H, Kaabeche K, Bouvard D, Sanjay A, Marie PJ. FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survival. Bone 2008; 42: 1032-1039.
108. Salingcarnboriboon RA, Pavasant P, Noda M. Cbl-b enhances Runx2 protein stability and augments osteocalcin promoter activity in osteoblastic cell lines. J Cell Physiol 2010; 224: 743-747.
109. Suzue N, Nikawa T, Onishi Y, Yamada C, Hirasaka K, Ogawa T et al. Ubiquitin ligase Cblb downregulates bone formation through suppression of IGF-I signaling in osteoblasts during denervation. J Bone Miner Res 2006; 21: 722-734.
110. Kumar EA, Charvet CD, Lokesh GL, Natarajan A. High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)-protein tyrosine kinase interactions. Anal Biochem 2011; 411: 254-260.
111. Ciechanover A, Schwartz AL. The ubiquitin system: pathogenesis of human diseases and drug targeting. Biochim Biophys Acta 2004; 1695: 3-17. (Pubitemid 39574964)
112. Lipkowitz S. The role of the ubiquitination-proteasome pathway in breast cancer: ubiquitin mediated degradation of growth factor receptors in the pathogenesis and treatment of cancer. Breast Cancer Res 2003; 5: 8-15. (Pubitemid 36553572)
113. Eldridge AG, O'Brien T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death Differ 2010; 17: 4-13.
114. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 2011; 10: 29-46.
115. Dahlmann B. Role of proteasomes in disease. BMC Biochem 2007; 8(Suppl 1): S3.
116. Jones MD, Liu JC, Barthel TK, Hussain S, Lovria E, Cheng D et al. A proteasome inhibitor, bortezomib, inhibits breast cancer growth and reduces osteolysis by downregulating metastatic genes. Clin Cancer Res 2010; 16: 4978-4989.
117. Ruschak AM, Slassi M, Kay LE, Schimmer AD. Novel proteasome inhibitors to overcome bortezomib resistance. J Natl Cancer Inst 2011; 103: 1007-1017.
118. Lipkowitz S, Weissman AM. RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 2011; 11: 629-643.
119. Shi D, Grossman SR. Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets. Cancer Biol Ther 2010; 10: 737-747.
120. Huang C. Roles of E3 ubiquitin ligases in cell adhesion and migration. Cell Adh Migr 2010; 4: 10-18.
121. Kales SC, Ryan PE, Nau MM, Lipkowitz S. Cbl and human myeloid neoplasms: the Cbl oncogene comes of age. Cancer Res 2010; 70: 4789-4794.
122. Peschard P, Park M. Escape from Cbl-mediated downregulation: a recurrent theme for oncogenic deregulation of receptor tyrosine kinases. Cancer Cell 2003; 3: 519-523. (Pubitemid 36808646)
123. Tan YH, Krishnaswamy S, Nandi S, Kanteti R, Vora S, Onel K et al. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases. PLoS One 2010; 5: e8972.
124. Kang JM, Park S, Kim SJ, Hong HY, Jeong J, Kim HS. CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-beta signaling. Oncogene 2012; 31: 5123-5131.
125. Lo FY, Tan YH, Cheng HC, Salgia R, Wang YC. An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer 2011; 117: 5344-5350.
126. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422-441. (Pubitemid 39014554)
127. Lian JB, Javed A, Zaidi SK, Lengner C, Montecino M, van Wijnen AJ et al. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr 2004; 14: 1-41. (Pubitemid 38581526)
128. Thomas DM, Johnson SA, Sims NA, Trivett MK, Slavin JL, Rubin BP et al. Terminal osteoblast differentiation, mediated by runx2 and p27KIP1, is disrupted in osteosarcoma. J Cell Biol 2004; 167: 925-934. (Pubitemid 39628114)
129. Martin JW, Zielenska M, Stein GS, van Wijnen AJ, Squire JA. The role of RUNX2 in osteosarcoma oncogenesis. Sarcoma 2011; 2011: 282745.
130. Pereira BP, Zhou Y, Gupta A, Leong DT, Aung KZ, Ling L et al. Runx2, p53, and pRB status as diagnostic parameters for deregulation of osteoblast growth and differentiation in a new pre-chemotherapeutic osteosarcoma cell line (OS1). J Cell Physiol 2009; 221: 778-788.
131. van der Deen M, Akech J, Lapointe D, Gupta S, Young DW, Montecino MA et al. Genomic promoter occupancy of runt-related transcription factor RUNX2 in osteosarcoma cells identifies genes involved in cell adhesion and motility. J Biol Chem 2012; 287: 4503-4517.
132. Pratap J, Lian JB, Javed A, Barnes GL, van Wijnen AJ, Stein JL et al. Regulatory roles of Runx2 in metastatic tumor and cancer cell interactions with bone. Cancer Metastasis Rev 2006; 25: 589-600. (Pubitemid 46071865)
133. Shapovalov Y, Benavidez D, Zuch D, Eliseev RA. Proteasome inhibition with bortezomib suppresses growth and induces apoptosis in osteosarcoma. Int J Cancer 2010; 127: 67-76.
134. Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS et al. Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 2008; 112: 2119-2129. (Pubitemid 351628620)
135. Sévére N, Dieudonné FX, Marty C, Modrowski D, Patino-Garcia A, Lecanda F et al. Targeting the E3 ubiquitin casitas B-lineage lymphoma decreases osteosarcoma cell growth and survival and reduces tumorigenesis. J Bone Miner Res 2012; 27: 2108-2117.
136. Ho AL, Schwartz GK. Targeting of insulin-like growth factor type 1 receptor in Ewing sarcoma: unfulfilled promise or a promising beginning? J Clin Oncol 2011; 29: 4581-4583.
137. Bedford L, Lowe J, Dick LR, Mayer RJ, Brownell JE. Ubiquitin-like protein conjugation and the ubiquitin-proteasome system as drug targets. Nat Rev Drug Discov 2011; 10: 29-46.
138. Marx C, Held JM, Gibson BW, Benz CC. ErbB2 trafficking and degradation associated with K48 and K63 polyubiquitination. Cancer Res 2010; 70: 3709-3717.
139. Williams SA, Maecker HL, French DM, Liu J, Gregg A, Silverstein LB et al. USP1 deubiquitinates ID proteins to preserve a mesenchymal stem cell program in osteosarcoma. Cell 2011; 146: 918-930.